Risk of thromboembolic events in patients with polycythaemia vera: a study based on german health claims data
Karina C Manz, Bashar Morouj, Marc Feuerbach, Rainer Ehneß, Pamela Lenti, Isabel Barnstorf, Ariane Höer, Haifa Kathrin Al-Ali · 2026
Read Risk of thromboembolic events in patients with polycythaemia vera: a study based on german health claims data by Karina C Manz, Bashar Morouj, Marc Feuerbach, Rainer Ehneß, Pamela Lenti, Isabel Barnstorf, Ariane Höer, Haifa Kathrin Al-Ali (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13275612.txt.
Description
Karina C Manz and colleagues present a 2026 journal article measuring clot risk in polycythemia vera, a blood cancer that overproduces red cells, using German health insurance claims from 2021 to 2023. They tracked blood-clot events, bloodletting frequency, and failure of the standard drug hydroxyurea, sorting patients into four risk groups by age and prior clots.
About a third of existing patients had blood drawn off each year, while newly diagnosed patients needed it more often. Patients with both risk factors, prior clot and age sixty or over, clotted at 82.4 events per thousand patient-years, over six times the low-risk rate. Their three-year clot incidence reached 21.1 percent. About twenty-two percent of hydroxyurea users showed intolerance or resistance after a median of 337 days, and they clotted more often than patients switched to ruxolitinib.
Catalog record
| CREATOR | Karina C Manz, Bashar Morouj, Marc Feuerbach, Rainer Ehneß, Pamela Lenti, Isabel Barnstorf, Ariane Höer, Haifa Kathrin Al-Ali |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37493 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |